SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
The filing discloses quarterly financial results for the three and six months ended June 30, 2026, with GAAP diluted EPS of $0.64 and $0.67 respectively, and ongoing diluted EPS of $0.58 and $0.79. The press release (Exhibit 99.1) presents detailed earnings data by segment (PNM, TNMP, Corporate and Other) with reconciliations between GAAP and non-GAAP measures, which is the hallmark of an earnings release under Item 2.02.
View raw filing on EDGAR →Anteris disclosed an inadvertent failure to lodge cleansing notices under Australian securities law (section 708A(6) of the Corporations Act) within the prescribed 5-business-day period following issuance of 44,068 CDIs on July 10, 2026. The company is seeking Federal Court relief under section 1322 of the Corporations Act to extend the filing deadline. While the company states it does not consider the oversight price-sensitive and lacked excluded information at issuance, the regulatory non-compliance and pending court application constitute a material legal/regulatory event requiring disclosure and triggering a trading halt on the ASX.
View raw filing on EDGAR →AmBase entered into a Litigation Funding Agreement on March 2, 2026 (with a $6M commitment) and a Letter Agreement on July 30, 2026 (with an additional $1M contribution) with Chairman/CEO Richard A. Bianco. These are structured financing arrangements creating direct financial obligations to repay the funder with multiples of 1.0x to 3.5x the funded amount plus fees and expenses. While labeled "litigation funding," the substance is a debt-like obligation that creates a new direct financial liability, fitting the debt_issuance category. The filing emphasizes going-concern uncertainty and the Company's need for capital, making this material to investors assessing the registrant's financial condition.
View raw filing on EDGAR →This Item 5.07 filing discloses the results of a special meeting of stockholders held on July 31, 2026, where shareholders voted on and approved three proposals: (1) the Transaction Proposal to approve a Membership Interest Purchase Agreement for Amneal to acquire 100% of Kashiv BioSciences, LLC; (2) the Stock Issuance Proposal to approve issuance of 28,942,108 shares of Common Stock to the sellers; and (3) an Adjournment Proposal (not submitted). The voting results show strong approval with 138,265,079 votes for the Transaction Proposal and 286,714,072 votes for the Stock Issuance Proposal. This is a material acquisition transaction requiring shareholder approval, making the vote results material to investors.
View raw filing on EDGAR →PDS Biotechnology received a deficiency letter from Nasdaq on July 30, 2026, notifying the company that its closing bid price has fallen below the $1.00 minimum required under Nasdaq Listing Rule 5550(a)(2). The company has been granted a 180-day compliance period (until January 26, 2027) to regain compliance, with the explicit warning that failure to do so will result in delisting. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →KKR entered into a Fourth Amended and Restated Credit Agreement on July 30, 2026, establishing a $3.0 billion senior unsecured multicurrency revolving credit facility with a five-year maturity, representing a material refinancing or amendment of the company's credit facility.
View raw filing on EDGAR →Electro Sensors Inc completed a merger transaction in which all outstanding shares of common stock were converted into $7.75 per share in cash consideration, with all compensatory options and RSUs becoming fully vested and converted to cash payments. The Company became a wholly owned subsidiary of the Parent company at the Effective Time of the merger.
View raw filing on EDGAR →As a result of the merger completion, the Company's Common Stock ceased trading on Nasdaq Capital Market on July 30, 2026. The Company requested suspension and removal from listing and intends to file Form 15 to deregister the Common Stock and suspend reporting obligations under the Exchange Act.
View raw filing on EDGAR →Four directors—David L. Klenk, Joseph A. Marino, Scott A. Gabbard, and Jeffrey D. Peterson—ceased to be directors of the Company at the Effective Time of the merger and were removed from all board committees.
View raw filing on EDGAR →This Item 8.01 disclosure concerns the Equity Residential–AvalonBay merger, an all-stock merger-of-equals transaction announced May 20, 2026, with the combined company to operate as Vivmark Residential. The filing updates shareholders on the merger's progress (S-4 registration statement declared effective July 13, 2026), shareholder litigation arising from alleged disclosure deficiencies in the proxy statement, and supplemental financial analyses and merger background information. Although styled as "Other Events," the core disclosure is the material acquisition activity and its status, making ma_activity the appropriate classification.
View raw filing on EDGAR →This is a quarterly earnings release for the second quarter ended June 30, 2026. The exhibit discloses financial results including Adjusted EBITDA of $291 million, Free Cash Flow of $143 million, and net earnings of $35 million, along with operational metrics and segment performance. While the release also mentions several significant events (executive changes, M&A activity, facility mothballing), the primary disclosure is the quarterly financial results announcement, which is material to investors assessing the registrant's operational and financial performance.
View raw filing on EDGAR →Diane Cafritz, Executive Vice President and Chief Innovation and People Officer, is departing CarMax effective December 31, 2026. While the filing also discloses severance and consulting arrangements, the principal disclosed action is the executive's departure. The material nature is supported by her senior officer status and the significant severance package (1.5x base salary plus full-year FY2027 bonus plus consulting fees totaling $360,500).
View raw filing on EDGAR →The press release announces that an Extraordinary General Meeting approved the appointment of Andrea Cesaroni as a member of the Executive Board, effective 31 July 2026, in the role of Chief Risk Officer (CRO). This is a material executive appointment to a named executive position at a major global financial institution, affecting the composition of the top leadership team alongside the CEO and CFO.
View raw filing on EDGAR →This is a press release announcing Brookfield Business Corporation's second quarter 2026 financial results, including net income of $37 million ($0.18 per Class A Share), Adjusted EBITDA of $587 million, and segment performance metrics. The disclosure includes consolidated financial statements and detailed operating results by business segment, which are characteristic of an earnings release. Material to investors assessing the registrant's financial performance and operational health.
View raw filing on EDGAR →This is a press release announcing Brookfield Renewable's second quarter 2026 financial results, including detailed consolidated financial statements (balance sheet, income statement, cash flows) and proportionate results by segment. The disclosure reports record FFO of $421 million ($0.62 per unit) for Q2 2026, up 13% year-over-year, and twelve-month FFO of $1,444 million ($2.14 per unit), up 14% year-over-year. The filing includes all hallmarks of a quarterly earnings release: financial tables, segment performance analysis, and management commentary on results.
View raw filing on EDGAR →Rubico has entered into a share purchase agreement to acquire 100% of the shares of a special purpose vehicle (SPV) that owns a shipbuilding contract for a 47,499 dwt MR tanker newbuilding, with a purchase price of approximately $6.5 million and expected closing by September 30, 2026. This constitutes a material acquisition under Item 1.01 of Form 8-K (or equivalent 6-K disclosure). The transaction is material to investors as it expands the company's fleet, increases contracted revenue backlog to $379.2 million, and was approved by an independent special committee with a fairness opinion.
View raw filing on EDGAR →The disclosure announces negative results from the ZEUS phase 3 cardiovascular trial of ziltivekimab, which failed to meet its primary endpoint (MACE risk reduction) despite achieving target biological engagement. The company explicitly states this will result in "a non-cash impairment charge in Q3 2026," indicating a material financial consequence. While the impairment itself is financial, the core event is the failure of a major clinical development program, which is an operational/strategic matter affecting the company's R&D pipeline and future product prospects.
View raw filing on EDGAR →This press release announces the successful completion of a business combination between Equinox Gold and Orla Mining, creating a combined North American senior gold producer with ~1.1 million ounces of annual production. The transaction is explicitly described as "previously announced" and "completed," representing a material acquisition/merger that fundamentally transforms the registrant's scale, asset portfolio, and operational structure. The disclosure also includes executive leadership changes (CEO succession, Chairman transition) directly tied to the transaction's completion.
View raw filing on EDGAR →Anfield Energy closed an underwritten public offering of 1,715,000 common shares at US$4.00 per share for aggregate gross proceeds of US$6.9 million. This is a registered equity issuance that dilutes existing shareholders. The participation of strategic investor Uranium Energy Corp. (625,000 shares for US$2.5 million) is explicitly noted as a related-party transaction under MI 61-101, and the company relied on exemptions from formal valuation and minority shareholder approval requirements. This material capital raise would affect a reasonable investor's assessment of ownership dilution and the company's financing strategy.
View raw filing on EDGAR →Item 7.01 discloses the company's post-earnings release conference call and webcast held on July 29, 2026 to discuss Q2 2026 financial results. The transcript (Exhibit 99.1) contains detailed discussion of quarterly earnings, including net sales of $158 million (19% increase YoY), diluted earnings of $0.43 per share, and adjusted EBITDA margin expansion to 10.5%. This is a standard earnings release disclosure furnished under Regulation FD.
View raw filing on EDGAR →Evogene held a contested 2026 Annual General Meeting on September 4, 2026, with a proxy contest involving competing director slates from the Board and activist shareholders (Pure Capital), along with shareholder votes on capital structure amendments including authorization for a reverse share split (1-for-2 to 1-for-15) and increase in authorized share capital. The Board issued an open letter defending its strategic direction and recommending shareholders vote for the Board's nominees while disregarding the activist shareholders' slate.
View raw filing on EDGAR →VSee Health issued an unsecured convertible promissory note for $336,000 principal to Labrys on June 30, 2026, with 12% interest and a maturity date of June 30, 2027. The note includes conversion rights into common stock and standard prepayment/acceleration provisions, creating a direct financial obligation material to the company's capital structure.
View raw filing on EDGAR →The filing discloses entry into the Fourth Amendment to a Business Combination Agreement dated July 31, 2026, whereby Blue Acquisition Corp. and Blockfusion will become wholly-owned subsidiaries of Blockfusion Digital Infrastructure, Inc. (Pubco), resulting in Pubco becoming a publicly traded company. This is a material acquisition/change of control transaction, properly disclosed under Item 1.01. The amendment extends the Outside Date but the underlying business combination remains a transformative M&A event.
View raw filing on EDGAR →Hanmi Financial Corporation completed a private placement of $55.0 million in aggregate principal amount of 6.50% Fixed-to-Floating Rate Subordinated Notes due 2036, structured to qualify as Tier 2 capital under Federal Reserve guidelines. The company intends to use proceeds to redeem $110 million of existing subordinated notes due 2031 and for general corporate purposes.
View raw filing on EDGAR →Citizens Financial Group issued 6.750% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series J with a $1,000 liquidation preference on July 30, 2026, materially modifying the rights of common and junior preferred shareholders through dividend restrictions and payment limitations.
View raw filing on EDGAR →MSD Investment Corp. entered into an Amended and Restated Senior Secured Credit Agreement on July 30, 2026, increasing aggregate commitments from $670.0 million to $920.0 million, increasing the maximum facility size to $1.380 billion, and extending the maturity date to July 30, 2031.
View raw filing on EDGAR →Bain Capital Specialty Finance entered into a Fourth Amendment to its Senior Secured Revolving Credit Agreement, extending the revolver availability period to July 26, 2030, extending the maturity date to July 28, 2031, and upsizing the total facility from $855 million to $905 million. This material modification of the Company's credit structure and $50 million facility increase constitutes a material modification of direct financial obligations.
View raw filing on EDGAR →This is a press release announcing GigaMedia's second-quarter 2026 unaudited financial results, dated July 31, 2026. The exhibit discloses consolidated revenues of $2.13 million (up 182.3% QoQ and 144.9% YoY), gross profit of $1.24 million, operating loss of $0.10 million, and net income of $0.55 million, along with detailed financial statements and management commentary. This is a discrete earnings announcement, not a periodic financial report filing, and the results are material to investors assessing the registrant's operational performance and financial condition.
View raw filing on EDGAR →BrightSpring issued a press release on July 31, 2026 announcing financial results for the quarter ended June 30, 2026, disclosing net revenue of $3,873 million (up 23.0%), net income of $87 million, and Adjusted EBITDA of $206 million (up 44.2%), along with increased full-year 2026 guidance. This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02, which is material to investors assessing the company's operational and financial performance.
View raw filing on EDGAR →The filing discloses a "Merger" effective July 30, 2026, in which six directors ceased serving and two new directors were appointed. While Item 5.02 typically covers executive changes, the reference to "in connection with the Merger" and the wholesale replacement of the board indicates this is fundamentally a change-of-control transaction. The merger itself is the material event; the board changes are consequences of it. This should be classified as ma_activity rather than exec_departure or exec_appointment, as the core disclosure is the merger completion.
View raw filing on EDGAR →This 6-K furnishes Sumitomo Mitsui Financial Group's consolidated financial results for the three months ended June 30, 2026, including quarterly consolidated balance sheets, statements of income and comprehensive income, and detailed notes. The document is explicitly titled "Consolidated Financial Results for the three months ended June 30, 2026" and contains full quarterly financial statements under Japanese GAAP, not a discrete event or press release announcing results. This is a periodic quarterly financial report itself, deferred for separate processing.
View raw filing on EDGAR →The filing discloses Enbridge's second quarter 2026 financial results via a press release dated July 31, 2026, attached as Exhibit 99.1. The disclosure includes GAAP earnings of $1.4 billion ($0.64 per share), adjusted earnings of $1.4 billion ($0.63 per share), adjusted EBITDA of $4.8 billion, and cash flow metrics, along with reaffirmed 2026 guidance. This is a standard quarterly earnings release under Item 2.02.
View raw filing on EDGAR →Church & Dwight issued a press release on July 31, 2026 announcing Q2 2026 financial results, including net sales of $1,530.0 million (+1.6%), organic sales growth of 5.8%, adjusted EPS of $0.89, and raised full-year 2026 guidance for sales, EPS, and cash flow. This is a standard quarterly earnings disclosure furnished under Item 2.02 as Exhibit 99.1.
View raw filing on EDGAR →Cameco reported consolidated financial and operating results for the second quarter ended June 30, 2026, with net earnings of $25 million, adjusted net earnings of $77 million, and adjusted EBITDA of $391 million, along with year-to-date comparative figures and segment performance metrics.
View raw filing on EDGAR →This is an announcement of Baidu's intention to report Q2 2026 financial results on August 18, 2026, with details of the earnings conference call. While the actual results are not yet disclosed in this exhibit, the announcement of the earnings release date and call logistics is a standard precursor to an earnings event. Baidu explicitly states it "will report its financial results for the Second Quarter 2026 ended June 30, 2026" on that date, making this a material disclosure of upcoming quarterly results.
View raw filing on EDGAR →This is a clear earnings release disclosing Tenax Therapeutics' financial results for Q2 2026 ended June 30, 2026. The Item 2.02 filing includes a press release (Exhibit 99.1) announcing quarterly financial results with condensed consolidated balance sheets and statements of operations showing net loss of $17.8 million for Q2 2026 versus $10.9 million in Q2 2025, along with cash position and operating expense details. This is material to investors as it provides the company's periodic financial performance and cash runway guidance through Q2 2028.
View raw filing on EDGAR →Inovio entered into an underwriting agreement on July 29, 2026 to issue 21,052,632 shares of common stock and warrants to purchase 42,105,264 additional shares in a registered public offering at $0.95 per share, with expected gross proceeds of approximately $20.0 million and net proceeds of approximately $18.3 million. The offering was priced on July 29, 2026 with expected closing on July 31, 2026.
View raw filing on EDGAR →Dominion Energy issued a press release on July 31, 2026, announcing preliminary unaudited earnings for the three months ended June 30, 2026, disclosing GAAP net income of $0.37 per share and operating earnings (non-GAAP) of $0.79 per share, along with reaffirmed full-year 2026 guidance. This is a standard quarterly earnings disclosure filed under Item 2.02 with detailed financial statements and segment results, which is material to investors assessing the company's financial performance.
View raw filing on EDGAR →Virax Biolabs Group Ltd is soliciting shareholder approval for three material proposals at an Extraordinary General Meeting scheduled for August 14, 2026: (1) a Share Capital Increase from 2 million to 500 million authorized ordinary shares (a 250x expansion providing significant transactional and financing flexibility), (2) adoption of amended and restated articles of association, and (3) an adjournment proposal.
View raw filing on EDGAR →The filing discloses receipt of two revised, non-binding unsolicited acquisition proposals to acquire all outstanding shares of Seer's Class A common stock: one from the Radoff-JEC Group at $2.55 per share plus a CVR, and one from CEO Dr. Farokhzad at $2.45 per share plus two CVRs. Although non-binding and subject to conditions, these represent material M&A activity requiring disclosure under Item 8.01, as they constitute entry into acquisition discussions that would materially affect a reasonable investor's assessment of the company's strategic alternatives and potential change of control.
View raw filing on EDGAR →This is a press release announcing SES S.A.'s H1 2026 financial results, including revenue of €1,602 million, Adjusted EBITDA of €725 million, and a reiterated full-year 2026 outlook. The document presents consolidated income statements, operational performance by business unit, and forward guidance, which are hallmarks of an earnings release. Material to investors as it discloses interim financial performance and updates guidance.
View raw filing on EDGAR →The Item 8.01 disclosure covers three distinct operational/clinical developments: (1) failure of the Phase 3 XPORT-EC-042 trial to meet its primary PFS endpoint in endometrial cancer, though a trend favored selinexor in the mITT subpopulation; (2) announcement of a planned sNDA submission for selinexor in myelofibrosis based on FDA feedback on SVR35 as a surrogate endpoint; and (3) disclosure that the Company is exploring financing transactions and strategic alternatives to extend cash runway. While the trial failure and regulatory pathway update are material clinical/operational milestones, and the financing exploration signals potential financial stress, none fit neatly into the specific taxonomy categories (no earnings release, no M&A completion, no going-concern language, no impairment charge). The disclosure is clearly operational/strategic in nature but spans clinical development, regulatory strategy, and capital-raising exploration, making `operational_other` the most appropriate classification.
View raw filing on EDGAR →The filing discloses a declaration of distributions to shareholders across three classes of common shares (Class S, I, and E) with specific per-share amounts ($0.13 gross, varying net amounts after servicing fees), a record date of July 31, 2026, and a payment date of approximately August 5, 2026. This is a routine but material dividend distribution disclosure typical of REITs, which are required to distribute substantially all taxable income to shareholders.
View raw filing on EDGAR →IonQ announced the completion of its acquisition of SkyWater Technology on July 31, 2026, pursuant to a Merger Agreement entered into on January 25, 2026. The transaction involved a two-step merger structure and consideration of $15.00 cash plus 0.4883 shares of IonQ common stock per SkyWater share. This is a material acquisition creating a vertically integrated quantum computing and semiconductor foundry company, directly affecting the registrant's business scope and financial position.
View raw filing on EDGAR →Portland General Electric issued a press release on July 31, 2026 announcing second quarter 2026 financial results, including GAAP net income of $68 million ($0.59 per diluted share) and non-GAAP net income of $74 million ($0.64 per diluted share), along with reaffirmed full-year 2026 adjusted earnings guidance of $3.33 to $3.53 per diluted share.
View raw filing on EDGAR →The Board renewed and increased the share repurchase plan from 5.0 million to 7.2 million shares through July 31, 2027. Share repurchase programs are a form of capital return to shareholders and fall within the dividend_distribution category, which encompasses "share-repurchase programs." The increase in authorization and extension of the plan term represent a material capital allocation decision affecting shareholder value.
View raw filing on EDGAR →Cameco announced that Westinghouse Electric Company (jointly owned by Cameco and Brookfield Renewable Partners) has confidentially submitted a draft S-1 registration statement for a proposed initial public offering. This represents a material change of control or disposition event — the potential public offering of a significant subsidiary would materially affect Cameco's ownership structure and capital position. While the IPO is still in draft stage and subject to market conditions, the confidential submission of the S-1 constitutes a material step toward a significant corporate transaction that would affect investor assessment of the registrant's assets and ownership.
View raw filing on EDGAR →The filing discloses a declaration of distributions to stockholders across four classes of common stock (Class I, D, T, and S), with gross distributions of $0.0770 per share and varying net distributions after stockholder servicing fees. The distributions are payable on or about August 5, 2026, and may be reinvested through the company's distribution reinvestment plan. This is a routine but material dividend declaration typical of a real estate investment trust (REIT).
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from the Fund's annual meeting held on July 30, 2026. The filing reports the final vote tallies for two proposals: election of a Class III Trustee (Mary Lee Schneider) and ratification of PricewaterhouseCoopers LLP as independent auditor, with specific vote counts for each proposal. This is the quintessential Item 5.07 disclosure and matches the shareholder_vote_results event type precisely.
View raw filing on EDGAR →The filing discloses the appointment of Daniel Gish as an independent trustee of the Board effective July 30, 2026, with committee assignments to the Nominating and Governance Committee and Audit Committee. While the section also mentions Daniel Kasell's resignation on July 29, 2026, the substantive focus and detail of the disclosure centers on Gish's appointment, including his background, qualifications, and independence certifications. Board-level appointments are material governance events affecting investor assessment of the company's leadership and oversight.
View raw filing on EDGAR →